Mental and Behavioral Health

Researchers examined the suicide rates of NCAA student-athletes from 2002 to 2022.

Test your pharmacy news knowledge with our weekly quiz.

A single dose of Compass Pathways’ investigational COMP360 was well tolerated and showed durable improvements in CAPS-5 and SDS total scores compared to baseline.

Check out this list of resources to share with patients who are experiencing mental health conditions.

With the mental health crisis worsening in the United States, recent research explores novel treatments and underlying causes.

The drug, TEV-749, demonstrated statistically significant and clinically meaningful efficacy results.

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

The Psychopharmacologic Drugs Advisory Committee will meet June 4 to review a new drug application from Lykos Therapeutics.

Two trials studying brexpiprazole in combination with sertraline "constitute one of the largest clinical development programs ever conducted in posttraumatic stress disorder (PTSD)."

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.

With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?

In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

See what's trending in pharmacy with a preview the Drug Topics April issue.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

The drug was previously approved in 2009 to treat schizophrenia.

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.

According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.

In a conversation at this year’s American Pharmacists Association Annual Meeting & Exposition, Sa’ed Al-Olimat outlined the potential of psychedelic therapeutics in treating mental health disorders.

Four posters presented at this year’s American Pharmacists Association Annual Meeting & Exposition assessed the potential impact of pharmacist interventions on improving mental health outcomes.

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

Stimulant medications are the first-line pharmacologic therapy for ADHD, but many of these medications are currently in short supply.

See what's trending in pharmacy with a preview the Drug Topics March issue.

Researchers studied the effect of wildfires on mental health in California from 2011 to 2018.

Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.

Medical spending on pediatric mental health conditions accounted for 46.6% of all pediatric medical spending in 2021.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

The increasing use of antidepressants observed before and after the public health crisis suggests a concerning mental health trend, especially among females.

On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.